Menopause and Sexual Health: Practices, Patient Attitudes and Treatment Gaps
Curriculum:
Menopause and Sexual Health: An Update on Dyspareunia and Female Sexual Dysfunction
Menopause and Sexual Health: An Update on Dyspareunia and Female Sexual Dysfunction
Credits:
0.75 ANCC Contact Hours 0.75 AMA PRA Category 1 Credit(s) ™
0.75 ANCC Contact Hours 0.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
January 12, 2018
January 12, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
OB/GYNs, Primary Care Physicians, Nurse Practitioners, Physician's Assistants, Endocrinologists
Relevant Terms:
Women's Health, Vulvovaginal atrophy, Genitourinary Syndrome of Menopause
Sheryl A. Kingsberg, Ph.D.
Sheryl A. Kingsberg, Ph.D.
Chief, Division of Behavioral Medicine
Department of OB/GYN
MacDonald Women’s Hospital
University Hospitals Cleveland Medical Center
Professor, Departments of Reproductive Biology and Psychiatry
Case Western Reserve University School of Medicine
Bio
.jpg)
Sheryl A. Kingsberg is a clinical psychologist and Professor in the Department of Reproductive Biology at Case Western Reserve University School of Medicine, and is the chief of the division of behavioral medicine in the department of OB/GYN at Case Medical Center, University Hospitals of Cleveland.Dr. Kingsberg is a past president of the International Society for the Study of Women’s Sexual Health (ISSWSH) and is an active member in numerous other national and international organizations including the American Psychological Association (APA), the American Society for Reproductive Medicine (ASRM), the Society for Sex Therapy and Research (SSTAR) and the North American Menopause Society (NAMS).
Irwin Goldstein, MD
Irwin Goldstein, MD Director of Sexual Medicine, Alvarado Hospital Clinical Professor of Surgery, University of California at San Diego Director, San Diego Sexual Medicine
Bio
Dr. Goldstein has been involved with sexual dysfunction research since the late 1970's. His interests include penile microvascular bypass surgery, surgery for dyspareunia, sexual health management post cancer treatment, physiologic investigation of sexual function in men and women, and diagnosis and treatment of sexual dysfunction in men and women. Dr. Goldstein has authored more than 350 publications in the field of sexual dysfunction, and edited books on erectile dysfunction and on women’s sexual health. He is also Editor-in-Chief of Sexual Medicine Reviews and past Editor-in-Chief of The Journal of Sexual Medicine, official journals of the International Society for Sexual Medicine, its regional affiliate societies, and the International Society for the Study of Women’s Sexual Health. Dr. Goldstein is Director of Sexual Medicine at Alvarado Hospital, Clinical Professor of Surgery at University of California at San Diego and Director of San Diego Sexual Medicine where he maintains his clinical practice.Dr. Goldstein holds a bachelor’s degree in engineering from Brown University, with an honors thesis in biomedical engineering. In 1975, he graduated from McGill University Faculty of Medicine in his hometown of Montreal, Quebec, Canada. He was on the faculty of Boston University School of Medicine for 25 years where he was Professor of Urology and Gynecology and founding Director of the former Institute for Sexual Medicine at BUSM. Dr. Goldstein is currently President of The Institute for Sexual Medicine, Inc., a charitable corporation for education and research in the field. He is President of the International Society for the Study of Women’s Sexual Health, a former President of the Sexual Medicine Society of North America, a member of the International Society for Sexual Medicine, the International Academy of Sex Research, the American Urological Association, the American Association of Sex Educators, Counselors and Therapists, and the International Society for the Study of Vulvovaginal Disease. The World Association for Sexual Health awarded the Gold Medal to Dr. Goldstein in 2009 in recognition of his lifelong contributions to the field, in 2012 he received the International Society for the Study of Women’s Sexual Health Award for Distinguished Service in Women’s Sexual Health, in 2013 the Sexual Medicine Society of North America awarded him their Lifetime Achievement Award and in 2014 he received the ISSM Lifetime Achievement Award from the International Society for Sexual Medicine.
| 1. | Express the physical, psychological, and interpersonal burden resulting from the symptoms of Genitourinary Syndrome of Menopause (GSM), Vulvovaginal atrophy (VVA), dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) after menopause | 2. | Explain the changes in genitourinary morphology that occur as a result of menopause |
| 3. | Review the benefits and limitations of traditional treatments for dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) | 4. | Explain the etiology of/and treatment options for Hypoactive Sexual Desire Disorder (HSDD) |
| 1. | Express the physical, psychological, and interpersonal burden resulting from the symptoms of Genitourinary Syndrome of Menopause (GSM), Vulvovaginal atrophy (VVA), dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) after menopause |
| 2. | Explain the changes in genitourinary morphology that occur as a result of menopause |
| 3. | Review the benefits and limitations of traditional treatments for dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) |
| 4. | Explain the etiology of/and treatment options for Hypoactive Sexual Desire Disorder (HSDD) |
Statement of Need/Program Overview
This activity is designed to raise awareness and knowledge of current GSM, VVA and dyspareunia diagnostic and treatment gaps while providing insights into the attitudes and perceptions of postmenopausal women suffering with these conditions. The impact of physiologic and morphologic vulvovaginal changes and the strengths and limitations of traditional estrogen-based treatments will be discussed.
Educational Objectives
After completing this activity, the participant should be better able to:
- Express the physical, psychological, and interpersonal burden resulting from the symptoms of Genitourinary Syndrome of Menopause (GSM), Vulvovaginal atrophy (VVA), dyspareunia and Hypoactive Sexual Desire Disorder (HSDD)
- Explain the changes in genitourinary morphology that occur as a result of menopause
- Review the benefits and limitations of traditional treatments for dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM)
- Explain the etiology of/and treatment options for Hypoactive Sexual Desire Disorder (HSDD)
Program Agenda
This activity will cover topics such as:
(1) Defining the postmenopausal vulvovaginal syndrome related to loss of sex steroids
(2) Understanding the attitudes and perceptions of postmenopausal women as well as the barriers to effective patient-healthcare practitioner dialogue
(3) The physiologic, histologic and morphologic changes characteristic of vulvovaginal atrophy and the genitourinary syndrome of menopause
(4) Hypoactive Sexual Desire Disorder (HSDD) and Dyspareunia after menopause
(5) Traditional estrogen treatments and treatment gaps
(1) Defining the postmenopausal vulvovaginal syndrome related to loss of sex steroids
(2) Understanding the attitudes and perceptions of postmenopausal women as well as the barriers to effective patient-healthcare practitioner dialogue
(3) The physiologic, histologic and morphologic changes characteristic of vulvovaginal atrophy and the genitourinary syndrome of menopause
(4) Hypoactive Sexual Desire Disorder (HSDD) and Dyspareunia after menopause
(5) Traditional estrogen treatments and treatment gaps
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provider-ship of Medical Education Resources (MER) and ReardenCME. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Medical Education Resources designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 0.75 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.75 contact hours.
Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Irwin Goldstein, MD, has served as a consultant, speaker, investigator, or on a scientific advisory board for Ascend, Emotional Brain, Nuelle, Shionogi, Valeant. He has received research grants/research support from: JoyLux, Palatin, TherapeuticsMD, and Valeant.
Sheryl A. Kingsberg, PhD, is a consultant, investigator or on a scientific advisory board for Acerus Pharmaceuticals, AMAG, Bayer, Emotional Brain, Endoceutics, Materna, Novo Nordisk, Nuelle, Palatin Technologies, Pfizer, Shionogi, Strategic Solutions Technologies (SST), TherapeuticsMD, Valeant, and Viveve.
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Planners at Medical Education Resources have no financial relationships to disclose.
Planners at ReardenCME have no financial relationships to disclose.
Method of Participation
There are no fees for participating in and receiving credit for this activity. During the period, January 12, 2018 through January 11, 2019, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest with a score of 60% or better by recording the best answer to each question in the answer key on the evaluation form, 4) complete the evaluation form, and 5) claim / submit for the certificate.
Media
Internet
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, ReardenCME, and/or Endoceutics. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.Fee Information
There is no fee for this educational activity.
MER Privacy Policy
Medical Education Resources and ReardenCME maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.
The only information MER obtains is information supplied voluntarily by the visitor.
We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.
We use the information to grade your posttest and to send you a certificate of completion of the activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.
For each activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the information to invite you to participate in other activities that we may offer.
Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us (800-421-3756).
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
